Ireland - English - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - glucose monohydrate; sodium chloride; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate ; sodium gluconate - solution for infusion - 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery.,arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.,arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe).,arixtra is indicated for the treatment of unstable angina or non-st segment elevation myocardial infarction (ua/nstemi) for whom urgent (<120 min) invasive management (pci) is not indicated.,arixtra is indicated for the treatment of st segment elevation myocardial infarction (stemi) in patients who are managed without any form of initial reperfusion therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

dlrc pharma services limited - sodium bicarbonate - solution for injection - 8.4 percent weight/volume - electrolyte solutions; sodium bicarbonate

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.

Malta - English - Medicines Authority

les laboratoires servier 50 rue carnot, 92284 suresnes cedex, france - trimetazidine dihydrochloride - modified-release tablet - trimetazidine dihydrochloride 35 mg - cardiac therapy

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - potassium chloride; glucose monohydrate - solution for infusion - 0.15 + 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates - blood substitutes and perfusion solutions; electrolytes with carbohydrates - prevention and treatment of potassium depletion and/or hypokalaemia in cases where supply of water and carbohydrates is required due to either restriction of the intake of fluids and electrolytes or depletion by normal routes

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - potassium chloride; glucose monohydrate - solution for infusion - 0.3 + 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates - blood substitutes and perfusion solutions; electrolytes with carbohydrates - prevention and treatment of potassium depletion and/or hypokalaemia in cases where supply of water and carbohydrates is required due to either restriction of the intake of fluids and electrolytes or depletion by normal routes.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - venlafaxine hydrochloride, quantity: 169.8 mg (equivalent: venlafaxine, qty 150 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; sunset yellow fcf; povidone; magnesium stearate; microcrystalline cellulose; brilliant blue fcf; copovidone; allura red ac; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - elaxine sr 150 is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - venlafaxine hydrochloride, quantity: 84.9 mg (equivalent: venlafaxine, qty 75 mg) - capsule, modified release - excipient ingredients: iron oxide black; colloidal anhydrous silica; ethylcellulose; iron oxide red; magnesium stearate; microcrystalline cellulose; povidone; purified talc; titanium dioxide; gelatin; copovidone; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - elaxine sr 75 is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.